US FDA approves Replimune's skin cancer drug after prior rejections
- Posted on August 6, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
US FDA approves Replimune's skin cancer drug after prior rejections
By Sneha S K and Kamal Choudhury Aug 6 (Reuters) - The U.S. Food and Drug Administration has approved Replimune's drug for a difficult-to-treat form of skin cancer, the company said on Thursday, giving the biotech firm its first marketed product after multiple regulatory setbacks. Replimune was seeking accelerated approval for RP1, now known as Tudriqev, in combination with Bristol Myers
